Signos, Inc.

Signos, Inc. is a US-based company focused on continuous glucose monitoring technology that helps individuals understand their metabolism and achieve healthier dietary choices. Founded in 2020 in Burlingame, US, Signos, Inc. specializes in metabolic health solutions.

The company is co-founded by Pierre Wehbe, Sharam Fouladgar-Mercer, and William Dixon, with Sharam Fouladgar-Mercer serving as the CEO. Signos has successfully raised USD 20. 00 mn in its Series B funding round, which is also the total amount raised across four deals. Notable investors include Cheyenne Partners, Dexcom Ventures, GV, and Samsung NEXT Ventures.

The company's current valuation stands at USD 108. 171 mn. Signos provides advanced continuous glucose monitoring (CGM) technology designed to assist users in tracking their metabolic responses to food. Their primary offering integrates the Dexcom G7 sensor with the Signos app, delivering real-time glucose readings and personalized dietary feedback.

The platform is aimed at health-conscious consumers focused on weight management and improved metabolic health, operating in key markets including the United States. Signos generates revenue through a subscription model, offering users access to its mobile application, personalized nutrition guidance, and essential hardware like the Dexcom G7 sensor. Membership plans are tailored for individual consumers, emphasizing long-term health and wellness, and facilitate direct-to-consumer transactions with their comprehensive glucose monitoring and coaching solutions. Looking ahead, Signos, Inc.

plans to expand its product line and enter new geographic markets. They aim to introduce new features and enhancements to their CGM technology. Recent funding will support these initiatives, including an undisclosed amount raised from new investor Reform Ventures, which reinforces their commitment to growth and innovation.